“In Q2, we saw continued progress against core development goals for each of the components of our platform,” said Sujal Patel, CEO of Nautilus. “We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to view as one of the most significant untapped opportunities in biological science.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
- Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
- Is NAUT a Buy, Before Earnings?
- Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
- Nautilus Biotechnology initiated with a Buy at Guggenheim
- Nautilus Biotechnology assumed with a Hold from Buy at Jefferies